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S U M M A R Y
Health care workers (HCWs) are considered at high risk of acquiring the hepatitis B virus (HBV).
Seroconversion rates after vaccination against HBV among HCWs have not previously been available in
Sri Lanka. In the current study, the response to HBV surface antigen (HBsAg) vaccine was assessed in a
selected group of HCWs by testing for antibodies against HBsAg (anti-HBs). This was a retrospective
descriptive study to measure the anti-HBs levels, using an ELISA, in an immunized group of HCW referred
to Department of Microbiology, Faculty of Medicine, University of Peradeniya, Sri Lanka. Among the 342
participants, 9.9% (n = 34) were non-responders. Female participants had a signiﬁcantly higher immune
response (94.7%) than males (p < 0.05). The results of the study found no signiﬁcant decline in the
immune response with time (p > 0.05). Post HBsAg vaccination immunity in HCW in Sri Lanka is similar
to that of global rates with similar gender variation. Anti-HBs levels should be tested in all HCW
following HBsAg vaccination so that necessary precautions can be taken.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis B virus (HBV) infection is an important occupational
risk to health care workers (HCW). HBV infection can be prevented
through HBV surface antigen (HBsAg) vaccination. Testing for
evidence of protective immunity to HBsAg vaccination is essential,
as some vaccinees do not develop sufﬁcient levels of antibodies
against HBsAg (anti-HBs).1 An anti-HBs titer of < 10 mIU/ml is
regarded as non-responsiveness to HBsAg vaccination.2 Anti-HBs
levels between 10 and 100 mIU/ml are regarded as hypo-
responsiveness and levels >100 mIU/ml are taken as a high level
of immunity. An anti-HBs level of >10 mIU/ml is generally
considered as protective against HBV infection.2 However, data on
the anti-HBs response to HBsAg vaccination are not available in Sri
Lanka, although Sri Lanka has been practicing HBV vaccination in
HCWs for more than 20 years. In the current study we tested the
response to HBsAg vaccination in a group of HCWs by detecting the
levels of anti-HBs.
2. Methods
The study population consisted of 342 HCWs vaccinated with a
standard course of HBsAg vaccination. The anti-HBs level was* Corresponding author. Tel.: +94 81 2396532; fax: +94 81 2389106.
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Germany). Data were analyzed categorically for gender, antibody
titer, age, and the time elapsed since the last dose of the
vaccination against anti-HBs levels using Minitab, version 14.
Comparisons were made using cross-tabulation with the Chi-
square test, and a p-value of <0.05 was considered statistically
signiﬁcant.
3. Results
The study population comprised 152 (44.4%) females and 190
(55.6%) males. Of the total participants, 325 (65.0%) had received
all three doses of vaccination and the rest had received two doses
only. Fifteen (4.4%) participants had taken the booster dose in
addition to their three-dose regimen vaccination. Overall, 9.9% of
the vaccinees did not develop a sufﬁcient anti-HBs response; 23.7%
had an anti-HBs titer between 10 and 100 mIU/ml and the rest
(66.4%) had an anti-HBs titer of >100 mIU/ml (Figure 1). The anti-
HBs response was signiﬁcantly higher in females when compared
to males (p = 0.027). Interestingly, no signiﬁcant association was
found between age and the immune response (p = 0.923) (Table 1)
for both genders. The anti-HBs titers were similar in the group of
participants who had received two doses and those who had
received three doses of the HBV vaccination, however all those
(n = 15) who had received a booster dose exhibited titers >100
mIU/ml. The time elapsed between the last dose of vaccination and
the time of assessment of anti-HBs levels ranged from 2 months toses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Descriptive characteristics of the study cohort including gender, age,
doses of HBsAg immunization received, duration after the last dose of the HBsAg
immunization, and the quantity of anti-HBs detected by a ELISA, as described in the
Methods.
Table 1
Gender and age groups of the study population
Characteristics <10 mIU/ml
n (%)
10–100 mIU/ml
n (%)
>100 mIU/ml
n (%)
p-Value
Gender
Male 26 (13.7) 46 (24.2) 118 (62.1) 0.027
Female 8 (5.3) 35 (23.0) 109 (71.7)
Age, years
<30 18 (9.2) 45 (23.0) 133 (67.9) 0.923
30–35 8 (11.3) 19 (26.8) 44 (62.0)
>35 8 (10.7) 17 (22.7) 50 (66.7)
Table 2
Time elapsed between the last dose of vaccination and the time of assessment for
immunity
Time elapsed No protection
(<10 mIU/ml)
n (%)
Protection
(>10 mIU/ml)
n (%)
p-Value
<1 year 16 (7.88) 187 (92.12) 0.304
1–7 years 13 (13.13) 86 (86.87)
>7 years 5 (12.50) 35 (87.50)
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reduced signiﬁcantly over the time (p = 0.304) (Table 2).
4. Discussion
The global level for a poor immune response to HBV
immunization in a given population is 5–10%.1 In our study 9.9%
of HCWs did not develop a protective level (<10 mIU/ml) of anti-
HBs, suggesting our results are compatible with global levels. Thepercentage of male non-responders (13.7%) was higher than their
female counterparts (5.3%) and similar ﬁndings have been reported
in previous studies.3,4 Smoking and certain genetic factors have
been proposed as probable reasons for a poor immune response to
HBV immunization in men; however, these were not evaluated in
our study.
It has been shown that when the age at vaccination is >40 years,
the rate of seroconversion to anti-HBs is less, whereas when the
age at vaccination is <40 years, seroconversion to anti-HBs is
higher than in the former subset.3,5 However, no association
between age at vaccination and the rate of seroconversion to anti-
HBs was found in the current study; this might be because the
majority of our study population was younger than 40 years of age.
Previous studies have demonstrated that the protection given
by HBV vaccine during childhood and adulthood lasts at least 15–
22 years in immunocompetent individuals.6–8 Our ﬁndings also
show that the immunity against HBV does not decline with time.
Hence the need for a booster after 7–10 years is not necessary in
immunologically competent healthy adults, as reported in a recent
comprehensive review.7 In agreement with the ﬁndings of the
recent review, some of the participants in our study had an anti-
HBs level >100 mIU/ml even 14 years after the last dose of HBV
vaccination. The immune response to the standard HBsAg
immunization in HCWs (90%) was similar to that observed in
HCWs in other parts of the world. Moreover, there were non-
responders who remain susceptible to HBV infection. The ﬁndings
of our study provide a base for testing for anti-HBs in vaccinees in
Sri Lanka.
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